Q3 and Full Year 2013 EPS GuidanceQ3 2013 EstimateFull Year 2013 Estimate(Low)(High)(Low)(High)GAAP results$0.03$0.05$(0.07)$(0.01)Goodwill impairment charge
——0.310.31Intangible asset impairment charges
——0.030.03Estimated acquisition-related net charges (credits)
0.020.020.010.00Estimated divestiture-related net credits
(0.01)(0.01)(0.02)(0.02)Estimated restructuring-related charges
——0.060.06Estimated amortization expense
An explanation of our use of these non-GAAP financial measures is provided at the end of this document.
Use of Non-GAAP Financial MeasuresTo supplement our unaudited condensed consolidated financial statements presented on a GAAP basis, we disclose certain non-GAAP financial measures, including adjusted net income and adjusted net income per share that exclude certain amounts, and revenue growth rates that exclude the impact of changes in foreign currency exchange rates. These non-GAAP financial measures are not in accordance with generally accepted accounting principles in the United States.
The GAAP financial measure most directly comparable to adjusted net income is GAAP net income and the GAAP financial measure most directly comparable to adjusted net income per share is GAAP net income per share. To calculate revenue growth rates that exclude the impact of changes in foreign currency exchange rates, we convert actual net sales from local currency to U.S. dollars using constant foreign currency exchange rates in the current and prior period. The GAAP financial measure most directly comparable to this non-GAAP financial measure is growth rate percentages using net sales on a GAAP basis. Reconciliations of each of these non-GAAP financial measures to the corresponding GAAP financial measure are included in the ac
|SOURCE Boston Scientific Corporation|
Copyright©2012 PR Newswire.
All rights reserved